Chatterjee S N
Arch Surg. 1976 Jun;111(6):680-3. doi: 10.1001/archsurg.1976.01360240060010.
Horse antihuman thymocyte globulin (HAHTG) combined with prednisone and azathioprine (lmuran) was used as immunosuppressive therapy in a randomized controlled sutdy in 50 renal allograft recipients. Side effects of HAHTG administration given intravenously were mostly mild. In the treated group, four patients out of 26 died of infectious complications, whereas in the control group, three patients out of 24 died of infectious complications (chi2 = .01,P greater than .05). The graft survival at 18 months was ten of 24 in the control group and ten of 26 in the treated group (chi2 = 1.26, P greater than .05). Cumulative graft survival was 58.3% in the control group and 38.1% in the treated group at 18 months. However, if we consider the people who died with a functioning graft not as graft failure but as if they left the study, then the cumulative graft survival is 64.5% in the control group and 65.9% in the treated group. Thus, the mortality from infective causes and graft survival were not significantly different between the two groups. Hence, we draw the conclusion that use of HAHTG did not exert a beneficial effect on the ultimate outcome.
马抗人胸腺细胞球蛋白（HAHTG）联合泼尼松和硫唑嘌呤（依木兰）被用作50例肾移植受者随机对照研究中的免疫抑制治疗。静脉注射HAHTG的副作用大多较轻。治疗组26例中有4例死于感染性并发症，而对照组24例中有3例死于感染性并发症（χ2 = 0.01，P＞0.05）。对照组18个月时移植物存活率为24例中的10例，治疗组为26例中的10例（χ2 = 1.26，P＞0.05）。18个月时对照组累积移植物存活率为58.3%，治疗组为38.1%。然而，如果我们将移植肾功能良好但死亡的患者不视为移植失败，而是视为退出研究，那么对照组累积移植物存活率为64.5%，治疗组为65.9%。因此，两组间感染性病因导致的死亡率和移植物存活率无显著差异。因此，我们得出结论，使用HAHTG对最终结局未产生有益影响。
